Martin Shkreli (AP Images)

Phar­ma men­ace Mar­tin Shkre­li's old com­pa­ny to pay up to $40M to states for Dara­prim price goug­ing

The Fed­er­al Trade Com­mis­sion and sev­en states on Tues­day an­nounced a new or­der un­der which the states will re­coup $40 mil­lion from phar­ma bad­boy Mar­tin Shkre­li, who’s cur­rent­ly in prison for se­cu­ri­ties fraud, and who spiked the price of an old, cheap tox­o­plas­mo­sis drug Dara­prim by 4,000% overnight.

The or­der fol­lows a Jan­u­ary 2020 com­plaint against Shkre­li, his as­so­ciate Kevin Mul­leady, who’s banned from work­ing in for phar­ma for 7 years, their com­pa­ny Vy­era Phar­ma­ceu­ti­cals and its par­ent com­pa­ny Phoenixus AG. The com­plaint al­leged that Shkre­li and Mul­leady not on­ly hiked the price of Dara­prim but used re­stric­tive dis­tri­b­u­tion and sup­ply agree­ments, as well as da­ta se­cre­cy, to il­le­gal­ly block cheap­er gener­ic ver­sions of the drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.